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clinical outcomes and medical resource utilization (MRU)
derived from the phase III ML17032 study. Direct medical costs
associated with trial-based MRU were based on Taiwan’s
National Health Insurance fee schedule for 2007. Costs associ-
ated with intravenous chemotherapy administration and adverse
event (AE) management were estimated by an expert panel
survey conducted among 12 oncologists. One-way sensitivity
analyses were performed on key model parameters by varying the
input values by 20%. RESULTS: A trend toward superior
progression-free survival was observed in the XP arm (median
5.6 months for XP vs. 5.0 for FP). Patients in the XP arm received
5.2 cycles of therapy vs. 4.6 cycles of FP. Compared to FP,
administration of XP required fewer consults per patient (5.2
for XP vs. 22.8 for FP). Chemotherapy drug cost was higher
(USD$1712) in the XP arm; however, these cost increments
were offset by differences of chemotherapy administration costs
(USD$4376) between two arms. AE proﬁles were similar and the
cost associated with grade 3/4 AE management were slightly
lower (USD $30) in the XP arm. Overall, XP was associated
with a cost saving of USD$2691(NTD$87,351). XP remained
cost-saving under one-way sensitivity analyses. CONCLUSION:
From the Taiwan BNHI perspective, this CMA demonstrates that
replacing FP by XP for the treatment of AGC would not only
save direct medical costs but also improve health outcomes in
Taiwan.
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OBJECTIVE: To undertake a cost-consequence analysis of
direct medical costs in the treatment of advanced oesophago-
gastric cancer based on the REAL 2 randomized clinical trial,
which demonstrated non-inferiority when oral capecitabine was
substituted for infusional 5FU as part of the standard regimen,
ECF. METHODS: Direct medical costs (2007 CDN$) from the
perspective of the Canadian public health system were applied
to resources (e.g., study treatment, toxicity management)
obtained from REAL 2 trial data available in the public
domain. Complete drug delivery was assumed. Mean overall
costs per patient were estimated over six cycles, corresponding
to treatment duration. RESULTS: The mean total cost per
patient treated with ECF was $9065 and $9268 for ECX. The
major driver of cost in the ECX arm is chemotherapy drug,
$5472 for capecitabine versus $2400 for infusional 5FU (6
cycles). This is offset by the cost of chemotherapy administra-
tion, $1551 for ECF compared to $671 for ECX, and central
venous access costs, $1230 for ECF. Additional line complica-
tion and hospitalization data were not available and therefore
not included in these estimates. Limited data on toxicity man-
agement, (e.g. febrile neutropenia, anemia, thromboembolism),
are available, and cost estimates are $2955 for ECF
and $2433 for ECX-treated patients. CONCLUSION: ECX has
similar efﬁcacy to ECF in the REAL 2 trial, but has potential
advantages in terms of patient preference and convenience of
an oral therapy. In addition, oral therapy decreases hospital
resource consumption. While drug costs for ECX are greater,
costs for chemotherapy administration and line-related costs
are substantially less, and underestimated in this analysis. Sub-
stituting capecitabine for infusional 5FU in the ECF regimen is
an attractive and affordable alternative for patients with
advanced oesophagogastic cancer.
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OBJECTIVE: In Finland, the overall costs of breast cancer man-
agement have increased, primarily during the last years by the
launch of expensive pharmaceutical therapies (trastuzumab in
2000). Economical reasons may therefore play a part in the
prescribing of new drugs. We analyzed with comprehensive time
series of all expenditures the effectiveness of pharmaceutical
developments and other interventions from 1987 to 2005.
METHODS: Finnish registry based data from 1987 to 2005 was
combined to evaluate all costs related to the care of breast cancer.
These included comprehensive health care costs, sick-leave
compensations, disability pensions, and loss of productivity;
all converted to 2004 euros. Several scenarios were thereafter
constructed to identify the important changes in care processes
and cost drivers during this period. RESULTS: During the obser-
vation period, the number of patients with breast cancer (5-year
survival prevalence) increased by 100% up to 17,000 patients
and the overall expenditure of care more than doubled from €70
to €160 million. The health care costs increased by 150% and the
cumulative costs per patient increased from €4500 to €5500. The
cost of medications has escalated with an overall increase of
660%, mostly during 2000’s. However, during this period, the
effectiveness of the treatment has increased as breast cancer
related deaths, in-hospital days and loss of productivity due to
premature deaths have decreased signiﬁcantly. Altogether, our
scenarios showed that new medications have had a beneﬁcial
ﬁnancial impact of 16–35 million € for the society during the
study period. CONCLUSION: Comprehensive assessment of
large patient cohorts and long term economical outcomes is a
useful method for evaluation of outcomes in chronic diseases.
Identiﬁcation of different cost drivers is needed as the cost of new
interventions is increasing and their beneﬁts should ideally be
assessed in relation to their broader societal inﬂuence.
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OBJECTIVE: This study provides updated, in-depth estimates of
colorectal cancer (CRC) treatment costs. METHODS: This ret-
rospective cohort study included patients aged 65 years, who
were recently diagnosed with colon (CC) or rectal (RC) cancer in
a SEER registry between 1996 and 2002 (n = 60,916) and 1:1
matched (by age, sex, geographic region) non-cancer comparison
patients from a 5% Medicare sample. We assigned costs to
phases as follows: 1) initial: costs in the period up to one year
after diagnosis among patients with 13 months survival; 2)
continuing: costs in the years between the initial and terminal
years among patients with36 months survival; and 3) terminal:
costs in the ﬁnal year of life. Terminal costs were assigned ﬁrst
(all costs considered terminal for patients who lived <13
months). Costs reﬂect all provider payments for cancer patients
in excess of those for matched comparison patients (2006 US
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Dollars). RESULTS: Cancer-related CRC costs averaged $32,303
in the initial phase, $3,548 per year in the continuing phase, and
$14,323 in the terminal phase. Initial-phase costs were similar by
site (CC: $32,528; RC: $31,701; P = 0.015), while continuing-
phase costs were roughly 1/3 higher for RC versus CC ($4,266
vs. $3,287; P < 0.001). Terminal-phase costs were $14,197
for CC and $14,654 for RC (P = 0.424). Initial-phase CC costs
were $17,278 and $40,501 for Stages 0 and 4, respectively
(P < 0.001), compared to $14,060 and $37,235 for Stage 0 and
4 RC (P < 0.001). Continuing costs ranged from $2,499–
$17,861 and $2,822–$17,741 for Stage 0–4 CC and RC patients,
respectively; terminal costs ranged from $7,814–$27,742 for
Stages 0–4 CC and $6,376–$20,047 for Stages 0–4 RC patients.
CONCLUSION: Excess costs associated with CRC are striking
and vary considerably by treatment phase, cancer site, and stage
at diagnosis. Interventions aimed at earlier diagnosis and preven-
tion have the potential to reduce cancer-related health care costs.
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OBJECTIVE: To determine how independent variables (e.g.,
gender, comorbidities, etc) predict total medical cost of lung
cancer in the two years following dignosis after we account for
the bias introduced by censoring. METHODS: Since health care
costs and utilization may be subject to right censoring and there-
fore are not always observable, the standard regression models
cannot be used to assess the effects of confounders. Inverse
Probability Weighted estimation is ideally suited to estimation
from non-random samples which might arise due to censoring or
by the censoring strategy used. IPW produces consistent estima-
tor with a covariance matrix that can be calculated by most
commercial statistics software. We applied a test to see if possible
censoring bias exists. We also calculated the deviation from the
consistent value if standard ordinary least square method was
used. RESULTS: A total of 201 patients with incident of cases of
lung were recruited from Michigan community hospitals and
their oncology units. We obtained Medicare claim ﬁles for the
two years following diagnosis. 28.8 percent of the cases were
censored, therefore their annual costs were not observed. The
total cost of all care is $60,429 for the two years following a
lung-cancer diagnosis and $55,877 for incomplete cases. Inverse
probability weighted results signiﬁcantly diverged from standard
regression model. There exist a selection bias (p = 0.000) there-
fore IPW estimation yielded consistent results. CONCLUSION:
This paper applies the inverse probability weighted estimation to
an inception cohort of patients newly diagnosed with lung
cancer. Our ﬁndings suggest that standard regression models
yields inconsistent estimator due to censoring bias. IPW least
square estimation method removes that bias.
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THE LIFETIME COST OF CERVICAL CANCER INTAIWAN
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OBJECTIVE: Cervical cancer is the top female cancer in terms of
incidence rate in Taiwan. Since July 1, 1995, the NHI program
has provided annual cervical smear tests for all women over the
age of 30. Besides, the vaccine for preventing cervical cancer has
been marketed in Taiwan in 2006. The purpose of this paper was
to estimate the lifetime (20 years) direct medical cost of cervical
cancer patients for future economic evaluation. METHODS: The
estimation of the lifetime cost based on insurer perspective and
incidence approach sourced from 1994–2002 cancer registry sta-
tistics of patients with cervical cancer and the claim data from
Taipei Veterans General Hospital (TPE-VGH). Totally, we have
2525 patients. Propensity score method was applied to match the
comparison group using the population claimed data from The
National Health Research Institutes (NHRI). The probabilities of
survival, dying of cancer or dying of other causes were estimated
through Cancer Registry statistics. We divided the whole disease
process into initial, continuing and terminal three phases. The
cost of cancer is the sum of the average cost of each phase.
Lifetime costs of cancers were estimated from the costs calculated
above incorporate survival rates of the cancers. RESULTS: The
results showed only 61 patients survived less than one year and
each patient spent US$13,358 during that period. For those
survived more than one year, terminal phase resulted in the
highest costs which was US$23,078. For those survived more
than one year, the initial phase cost for each patient was
US$4157 and the monthly cost for continuing phase was
US$113. The expected lifetime cost (20 years) of average cervical
cancer patient was US$30,238. CONCLUSION: Our study
provided critical information for the economic evaluation of
Pap smears screening and the vaccination program for human
papilloma virus.
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OBJECTIVE: Currently, two out of every 100,000 people
develop Chronic Lymphocytic Leukemia (CLL) annually. Over
90% of cases are found in people who are older than 50 years
of age. As the United States population ages over the next
two decades signiﬁcantly more patients with CLL are likely
to be diagnosed resulting in increased spending on CLL.
METHODS: Prevalence estimates of CLL in various age
cohorts from Surveillance Epidemiology and EndResults
(SEER) data combined with population demographics from the
United States Census Bureau are used to project the direct costs
associated with CLL over the next two decades. Sensitivity
analysis is conducted around all estimates to assess key model
parameters. RESULTS: In 2006, the average direct cost of
treatment was estimated at $304 million this is estimated to
increase to 333 million by 2010 and over 413 million in 2020;
an increase of 27% in the numbers of individuals in need of
treatment. These conservative cost estimates are based on
changing demographic distributions and do not include
increases in the costs of health care delivery, treatments or indi-
rect costs. The total costs of CLL are expected to reach over
1.5 billion USD by the year 2020. CONCLUSION: This work
reviews the literature on the economic costs associated with
CLL and based on expected demographic changes to the United
States population, identiﬁes an area of increasing concern to
health care policy makers and providers of clinical services to
oncology patients.
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